pentobarbital will decrease the level or outcome of cobimetinib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Prevent coadministration. Powerful or moderate CYP3A inducers may perhaps decrease cobimetinib systemic exposure by >80% and decrease its efficacy.pentobarbital will decrease the extent or result of phenytoin